Drugs Made In America Acquisition Corp.

What they do

The company has no operations and has generated no revenue. It was formed to effect a merger, share exchange, asset acquisition or similar business combination with one or more businesses. While it may pursue a target in any industry or geography, it intends to focus its search on the pharmaceutical industry.

Revenue drivers

• Trust account interest income — The only recurring economic inflow is interest earned on proceeds held in the trust account; the company otherwise generates no revenue.
• No operating segments — The company reports no segment or product revenue because it has never conducted business operations.

Recent performance

At June 30, 2026, total assets were $146.9 million, total liabilities were $9.1 million, and shareholder equity was negative $7.4 million. Cash and equivalents stood at $20,280. Annual net income for 2025 was $5.9 million, while operating cash flow for 2025 was negative $539,187. The company remains a shell company with nominal assets outside the trust account.

Strategy

Management intends to combine with a target business, focusing its search on the pharmaceutical industry, using IPO and private placement proceeds, shares, debt or a combination. The company has up to 15 months from the January 29, 2025 IPO close to consummate a business combination, extendable without shareholder approval up to two times by three months each. On April 14, 2026, it filed a proxy statement for an April 27, 2026 extraordinary general meeting proposing a charter amendment. Multiple material agreements have been disclosed via 8-K filings between March and September 2026.

Risks

• No operating history — The company has no operations or revenue, so its ability to complete a business combination depends on external financing and target availability.
• Combination deadline — It must complete an initial business combination within 15 months of the IPO close, or up to 21 months with sponsor-funded extensions, or face liquidation.
• Negative shareholder equity — Shareholder equity was negative $7.4 million at June 30, 2026, reflecting accumulated losses and offering costs outside the trust account.
• Limited unrestricted cash — Cash and equivalents of $20,280 at June 30, 2026 are far below the scale of expenses needed to pursue a target, restricting flexibility.

Outlook

The company continues to pursue an initial business combination, with a stated focus on the pharmaceutical industry. A charter amendment was proposed at an April 27, 2026 shareholder meeting, and several material agreements have been disclosed since March 2026. Management has not disclosed a specific target or transaction terms in the excerpts provided.